These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 3019810)
41. The non-effect of pirenzepine in dietary resistant irritable bowel syndrome. Gilvarry J; Kenny A; Fielding JF Ir J Med Sci; 1989 Oct; 158(10):262. PubMed ID: 2559903 [TBL] [Abstract][Full Text] [Related]
42. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. Kennedy T; Jones R; Darnley S; Seed P; Wessely S; Chalder T BMJ; 2005 Aug; 331(7514):435. PubMed ID: 16093252 [TBL] [Abstract][Full Text] [Related]
43. Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine. El-Haggar SM; Hegazy SK; Abd-Elsalam SM; Bahaa MM Biomed Pharmacother; 2022 Jan; 145():112399. PubMed ID: 34775240 [TBL] [Abstract][Full Text] [Related]
44. Role of ispaghula husk in the management of irritable bowel syndrome (a randomized double-blind crossover study). Golechha AC; Chadda VS; Chadda S; Sharma SK; Mishra SN J Assoc Physicians India; 1982 Jun; 30(6):353-5. PubMed ID: 6302072 [No Abstract] [Full Text] [Related]
45. [Treatment of colonic diverticulosis and irritable colon with wheat bran]. Levitan MKh; Dubinin AV; Beiul EA; Iurkov MIu; Shechovskaia AK Sov Med; 1981; (8):109-12. PubMed ID: 6270832 [No Abstract] [Full Text] [Related]
46. Comparative evaluation of efficacy and safety of drotaverine versus mebeverine in irritable bowel syndrome: A randomized double-blind controlled study. Rai RR; Nijhawan S Saudi J Gastroenterol; 2021; 27(3):136-143. PubMed ID: 33642357 [TBL] [Abstract][Full Text] [Related]
47. Controlled treatment trials in the irritable bowel syndrome: a critique. Klein KB Gastroenterology; 1988 Jul; 95(1):232-41. PubMed ID: 3286362 [TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome. McCrone P; Knapp M; Kennedy T; Seed P; Jones R; Darnley S; Chalder T Eur J Gastroenterol Hepatol; 2008 Apr; 20(4):255-63. PubMed ID: 18334867 [TBL] [Abstract][Full Text] [Related]
49. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. Ritchie JA; Truelove SC Br Med J; 1979 Feb; 1(6160):376-8. PubMed ID: 32949 [TBL] [Abstract][Full Text] [Related]
50. A double-blind placebo-controlled crossover study of mebeverine and mefenamic acid in the treatment of primary dysmenorrhoea. Langrick AF; Gunn AD; Livesey H; Whitehead AM Br J Clin Pract; 1989 Sep; 43(9):317-21. PubMed ID: 2620043 [TBL] [Abstract][Full Text] [Related]
51. [Controlled clinical study of the action of mebeverine hydrochloride in the treatment of irritable colon]. Secco GB; Di Somma C; Arnulfo G; Ricci C Minerva Med; 1983 Mar; 74(13):699-702. PubMed ID: 6339996 [TBL] [Abstract][Full Text] [Related]
52. Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. Centonze V; Imbimbo BP; Campanozzi F; Attolini E; Daniotti S; Albano O Am J Gastroenterol; 1988 Nov; 83(11):1262-6. PubMed ID: 3055943 [TBL] [Abstract][Full Text] [Related]
53. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial. Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995 [TBL] [Abstract][Full Text] [Related]
54. The effect of a new musculotropic subtance 9(Mebeverine) on irritable colon. De Groote J; Standaert L Tijdschr Gastroenterol; 1968; 11(5):524-8. PubMed ID: 5716156 [No Abstract] [Full Text] [Related]
55. Effects of wheat bran and Olestra on objective measures of stool and subjective reports of GI symptoms. McRorie J; Kesler J; Bishop L; Filloon T; Allgood G; Sutton M; Hunt T; Laurent A; Rudolph C Am J Gastroenterol; 2000 May; 95(5):1244-52. PubMed ID: 10811335 [TBL] [Abstract][Full Text] [Related]
56. The effect of wheat bran fiber and calcium supplementation on rectal mucosal proliferation rates in patients with resected adenomatous colorectal polyps. Alberts DS; Einspahr J; Ritenbaugh C; Aickin M; Rees-McGee S; Atwood J; Emerson S; Mason-Liddil N; Bettinger L; Patel J; Bellapravalu S; Ramanujam PS; Phelps J; Clark L Cancer Epidemiol Biomarkers Prev; 1997 Mar; 6(3):161-9. PubMed ID: 9138658 [TBL] [Abstract][Full Text] [Related]
57. The use of dietary fiber in the management of simple, childhood, idiopathic, recurrent, abdominal pain. Results in a prospective, double-blind, randomized, controlled trial. Feldman W; McGrath P; Hodgson C; Ritter H; Shipman RT Am J Dis Child; 1985 Dec; 139(12):1216-8. PubMed ID: 2998181 [TBL] [Abstract][Full Text] [Related]
58. Dietary fibre and the irritable bowel syndrome. Fielding JF; Melvin K J Hum Nutr; 1979 Aug; 33(4):243-7. PubMed ID: 479584 [TBL] [Abstract][Full Text] [Related]
59. Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study. Cook IJ; Irvine EJ; Campbell D; Shannon S; Reddy SN; Collins SM Gastroenterology; 1990 Jan; 98(1):66-72. PubMed ID: 2152777 [TBL] [Abstract][Full Text] [Related]
60. A Potential Role of Ethosuximide and Pentoxifylline in Relieving Abdominal Pain in Irritable Bowel Syndrome Patients Treated with Mebeverine: A Randomized, Double-Blind, Placebo-Controlled Trial. El-Haggar SM; Hegazy SK; Abd-Elsalam SM; Elkaeed EB; Al-Karmalawy AA; Bahaa MM J Inflamm Res; 2022; 15():1159-1172. PubMed ID: 35221706 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]